drugset / Trial / NCT05686798

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

NCT05686798 ↗

Phase 1 Recruiting 18 enrolled Henry Ford Health System
NaSequentialOpen-labelTreatment

Summary

The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.

Timeline

Start
2022-11-29
Primary completion
2027-01
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad5-yCD/mutTKSR39rep-ADP Unknown 1e+11 unknown Other
Subject Ad5-yCD/mutTKSR39rep-ADP Unknown 3e+11 unknown Other
Subject Ad5-yCD/mutTKSR39rep-ADP Unknown 1e+12 unknown Other